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REVIEW
Abstract: The development of stent has been a major advance in the treatment of obstructive
coronary artery disease since the introduction of balloon angioplasty. However, neointimal
hyperplasia occurring within the stent leading to in-stent restenosis is a main obstacle in the
long-term success of percutaneous coronary intervention (PCI). The recent introduction of
drug-eluting stents (DES) contributes a major breakthrough to interventional cardiology. Many
large randomized clinical trials using DES have shown a remarkable reduction in angiographic
restenosis and target vessel revascularization when compared with bare metal stents. The
results of these trials also appear to be supported by evidence from everyday practice and
noncontrolled clinical trials. However, the expanded applications of DES, especially in treating
complex lesions such as left main trunk, bifurcation, saphenous vein graft lesions, or in-stent
restenosis, are still under evaluation with ongoing studies. With the availability of different
types of DES in the market, the issue of cost should not be a deterrent and DES will eventually
be an economically viable option for all patients. The adoption of DES in all percutaneous
coronary intervention may become a reality in the near future. In this review article, we
summarize the recent development and progress of DES as well as compare and update the
results of clinical trials.
Keywords: drug-eluting stent, percutaneous transluminal coronary angioplasty, in-stent
restenosis
Introduction
Background of drug-eluting stent development
After the advent of cardiac catheterization in the late 1920s and the development of
coronary angiographic technology in the late 1950s, balloon angioplasty (BA) was
introduced in the mid 1960s. Balloon angioplasty was first applied to the
revascularization of the femoral, popliteal, and renal arteries, and was adapted to the
coronary arteries in the late 1970s (Forssmann 1929; Dotter and Judkins 1964; Hurst
1985, 1986). There were important limitations of coronary BA, including the risk of
uncontrollable plaque disruption and vascular recoil that may lead to periprocedural
coronary occlusion and myocardial infarction, and a 20%–40% incidence of restenosis
within 6–12 months after successful revascularization,
 which compromises the long-
term prognosis (Miller et al 1999). Various atherectomy techniques such as rotational
atherectomy (rotablation), Excimer Laser Coronary Angioplasty (ELCA), and
Directional Coronary Atherectomy (DCA) were developed in late 1980s and early
1990s, but these devices did not significantly improve the long-term outcome due to
a lack of an impact on restenosis rate (Mueller et al 1995; Karthikeyan et al 2004).
On the other hand, scaffolding metallic mesh, called stent, was developed during the
same period to prevent restenosis after BA. The clinical efficacy of stent compared
with conventional BA was studied in two landmark clinical trials. The North American
Stent Restenosis Study (STRESS)
 showed a lower angiographic restenosis rate (31.6%
vs 42.1%) and a lower target vessel revascularization (TVR) rate (10.2% vs 15.4%)
in stent group than in BA group (Fischman et al 1994). The European comparison of
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balloon-expandable-stent implantation with BA in patients
with coronary artery disease by the Benestent Study Group
proved a similar, but more impressive, reduction of restenotic
rate (22% vs 32%) (p = 0.02) and TVR rate (13.1% vs 22.9%)
(p = 0.005) in stent group compared with BA group (Serruys
et al 1994). Based on the result of these two studies, Palmaz-
Schatz balloon-expandable stent (Cordis Corp; a Johnson
and Johnson Company, Warren, NJ, USA) was approved as
the first bare metal stent (BMS) for elective use by Food
and Drug Administration (FDA) in 1994
 after Gianturco-
Roubin coil stent (Cook Inc, Bloomington, IN, USA) was
approved as the first BMS for acute closure in 1993 (Mueller
et al 1995). However, the sudden occlusion of vessel due to
subacute stent thrombosis (SAT) and late in-stent restenosis
(ISR) are two major complications that were initially
encountered with the widespread use of BMS. Although
the SAT rate has been reduced to approximately 1%
with adequate antiplatelet therapy (ie, aspirin and
clopidogrel), the incidence of ISR is still a hindrance to the
long-term success of the stenting procedure (Schomig et al
1996,  1997). When the use of BMS was expanded in the
high-risk restenosis groups of patients such as those with
small vessel, long and bifurcation lesions, and diabetes
mellitus, ISR and TVR escalated to the range of 50%–60%
and 30%–50%, respectively (Yokoi et al 1996). Extensive
research was carried out in the late 1990s to seek a solution
to the problem of ISR. Brachytherapy with insertion of
radioactive devices in the coronary artery was initially
developed to prevent ISR (Raizner et al 2000). Despite its
moderate success, brachytherapy had limitations such
as late thrombosis, geographic mismatch, relatively high
cost, and requirement of radiation oncologists, which
made it unsuitable for widespread and routine clinical
practice (Raizner et al 2000). During the period when
the brachytherapy was becoming the treatment of choice
of in-stent restenosis, clinical trials of drug-eluting stents
(DES) demonstrated a pristine outcome with a very high
success rate and very low in-stent restenosis rate. DES
has now become the mainstream therapy of coronary
artery stenosis due to the expected very low rate of
in-stent restenosis and brachytherapy has become a thing
of the past.
Figure 1 Pathophysiology of in-stent restenosis and the mechanisms of action of different therapeutic agents.
Abbreviations: ECM, extracellular matrix; SMC, smooth muscle cells.
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Pathophysiology of ISR and mechanism
of action of DES to prevent ISR
Three distinct processes are involved in the pathogenesis of
ISR as depicted in Figure 1. These include: (1) immediate
vessel recoil after stretch injury, (2) negative arterial
remodeling, and (3) neointimal hyperplasia (Hoffmann et
al 1996; Mintz et al 1996; Liu et al 2002; Muhlestein et al
2002). Elastic recoil is the immediate shrinkage of vessel
after percutaneous coronary intervention (PCI) due to the
elastic properties of arterial wall, which usually occurs
within 24 hours after procedure. Negative remodeling is a
process of local contraction of arterial wall and narrowing
of the lumen at the injured vascular segment. It may be
related to the healing process as well as the interaction
between endothelial cells and nonlaminar blood flow (Liu
et al 1989). Neointimal hyperplasia is the proliferation and
migration of smooth muscle cells from the media, possibly
circulating cells from bone marrow into the intima, and then
encroach on the vascular lumen (Liu et al 1989). Negative
remodeling and neointimal proliferation usually occur weeks
to months after PCI (Liu et al 1989). The first two
pathological processes were the main causes of restenosis
in BA, but were basically eliminated by use of stent. The
third mechanism, neointimal hyperplasia, becomes the only
major mechanism in the pathogenesis of ISR (Virmani and
Farb 1999).
Mechanism of neointimal hyperplasia
Immediately after stenting, the denuded endothelial surface
and disrupted medial tissue of arterial wall due to mechanical
trauma triggered an inflammatory process, which led to
platelet adhesion, activation, and aggregation, and
subsequently fibrin deposition and thrombus formation
within the stent (thrombotic phase: day 0–3) (Liu et al 1989).
These microthrombi as well as the stretch injury of the vessel
wall attract inflammatory cells such as macrophages and
lymphocytes, which demarginate from the bloodstream and
also from vasa vasorum (recruitment phase: day 3–8). These
inflammatory cells stimulate the production of various
growth factors and cytokines locally, which activate the
dormant (G0 phase) vascular smooth muscle cells in the
media and also possibly recruit the circulating stem cells to
re-enter into cell cycle and replicate. These proliferating
smooth muscle cells subsequently migrate into the intima
and thrombus in the stent lumen and eventually form a
neointimal layer within the stent lumen (proliferative phase:
day 8, healing) (Schwartz et al 2003). Even though cell
proliferation ceases at 2 weeks after the initial injury, these
smooth muscle cells continue to produce abundant
extracellular matrix, which leads to increased neointimal
volume. If this process of neointimal growth is exuberant
and significantly encroaches on the vascular lumen, it will
lead to ISR (Schwartz et al 2003). As a deeper vascular wall
injury stimulates a higher degree of neointimal hyperplasia,
the stent deployment injury actually induces more
neointimal tissue growth than the BA injury (Schwartz et al
1992).
Stent-based drug delivery system
The main processes of ISR, smooth muscle cell activation
and replication, occur locally at the site of injury. Therefore,
one of the most logical approaches is a stent-based drug
delivery system to locally deliver an appropriate
concentration of an effective agent to stop this process
without systemic toxicity. An effective system would consist
of 3 components: (1) a metallic platform, (2) a drug carrier
vehicle that stores a therapeutic agent as well as allows the
agent to diffuse into the vascular tissue in a controlled
fashion, and (3) an effective therapeutic agent that reduces
the neointimal growth induced by stent implantation.
The cross-section of a stent strut with typical coating
configuration can be seen in Figure 2. Therefore, an ideal
DES to achieve the greatest clinical efficacy and safety
is one that requires an optimization of these three
essential parameters.
Stent design in relation to even drug
distribution to vessel wall
The effect of different stent designs on the drug distribution
pattern has been scrutinized in experimental studies and also
tested in clinical trials (Hwang et al 2001; Takebayashi et al
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Figure 2 Cross-section of a stent strut with a drug-loaded polymeric coating.Vascular Health and Risk Management 2005:1(4) 266
Htay and Liu
2004). Recent experimental data suggest that the stent strut
configuration directly determines the pattern and degree of
drug delivery achieved by DES (Hwang et al 2001). The
simple proximity of stent struts to vascular tissue does not
ensure adequate drug delivery and distribution because most
nonuniform distribution has been found in the layers of the
artery closest to the stent (Hwang et al 2001). After
deployment of even highly lipid-soluble and rapidly
diffusing agents, homogeneous drug delivery throughout
the vessel with uniform concentration at various depths of
the vessel wall was not achieved in their study. In the same
study, the uniformity of drug distribution was found to be
increased with the strut number as well as significantly
dependent on the strut pattern of distribution. Therefore, a
symmetric expansion of stents with homogeneous
distribution of struts is essential for the optimization of drug
distribution (Figure 3). The importance of this concept was
further verified by a recent clinical study using Sirolimus-
eluting stent (SES) (Takebayashi et al 2004). In the latter
study, a nonuniform stent strut distribution and a greater
gap distance between struts after stent implantation resulted
in more neointimal hyperplasia (Takebayashi et al 2004).
Although a large number of stent designs have been
developed to date, only the multicellular design is currently
most commonly used; they can be categorized into “closed
cell” and “open cell” configurations (Rogers 2002). A closed
cell stent has a uniform cell expansion and constant cell
spacing when deployed in a curved vascular segment, which
gives more uniform drug distribution (Rogers 2002). An
open cell stent has a greater variation in the surface coverage
between the inner and outer curvatures in the curved
segment, but gives better conformability to curved surface
at the expense of less uniform drug distribution (Figure 3)
(Rogers 2002). The majority of current BMS use a closed
cell design. In summary, the optimal stent design for drug
delivery should have a large stent surface area, a small cell
gap, and minimal strut deformation after deployment while
maintaining conformability, radial support, and flexibility
to reach the complex coronary lesions.
Coating matrix as a reservoir for drugs
and controller of kinetic drug release
Many methods of coating stents with drugs have been
developed for DES (Figure 4). Some drugs can be bonded
directly to a metal stent (eg, prostacyclin, paclitaxel), but
most of the agents must be bonded to a matrix polymer,
which acts as a drug reservoir to ensure drug retention during
deployment and a uniform distribution on the stent (Sousa
et al 2003a). The types, compositions, and designs of the
polymers coated on the stent dictate the eluting kinetic of
the sustain time release of the drug over a period of weeks
or months following the implantation in situ. The coating
materials can be categorized as organic vs inorganic,
bioerodable vs nonbioerodable, and synthetic vs naturally
occurring substances (Sousa et al 2003a). Generally, for
long-term application, a nonbioerodable polymer is used in
order to prevent triggering an inflammatory process. The
most successfully tested DESs to date have been coated with
synthetic polymers; poly-n-butyl methacrylate and
polyethylene-vinyl acetate with sirolimus and a poly
(lactide-co-Σ-caprolactone) copolymer with paclitaxel-
eluting stents. All naturally occurring organic materials are
both bio- and hemo-compatible (Ratner 1993; De Scheerder
et al 2000). Fibrin, cellulose, and albumin have been tested
in animal models, but only phosphorylcholine is used for
clinical purposes. Phosphorylcholine is a naturally occurring
phospholipid polymer with less potential to elicit
inflammation and to interfere with re-endothelialization of
the stent surface (Lewis et al 2002). BiodivYsio
® stents are
phosphorylcholine-coated stents currently available (Galli
et al 2000). Inorganic substances have also been tested for
coating on the stent surface to improve electrochemical
properties. One example is a stent coated with a nonporous
Figure 3 Uniform vs nonuniform drug distribution in closed cell vs open cell
stents was shown in the longitudinal sections of the vessel wall after a
deployment of a drug-eluting stent. Drug concentration was shown in the color
intensity in the column. Upper red-brown color is the highest and lower blue
color is the lowest drug concentration. (Upper panel). A cross-section of vessel
after a deployment of a drug-eluting stent depicts nonuniform strut spacing
resulting in uneven drug distribution (Lower panel).
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300 µm ceramic layer containing tacrolimus-loaded
nanocavities (Grube et al 2003).
Therapeutic agents to inhibit neointimal
growth
Many agents with antiinflammatory or antiproliferative
properties have been incorporated on the stent surface and
tested clinically (Tables 1 and 2). Many of the agents listed
in the tables have more than one mechanism of action. The
general mechanism of action for most of these drugs is to
stop cell cycle progression by inhibiting DNA synthesis.
Everolimus, sirolimus, tacrolimus (FK-506), ABT-578,
interferon, dexamethasone, and cyclosporine all fall into this
category. In this group, sirolimus and its derivatives were
shown to reduce intimal thickening (Sousa et al 2001; Sousa,
Costa, et al 2003). Dexamethasone-coated BiodivYsio stent
also showed a mild to moderate benefit in reducing
restenosis (Liu et al 2002). Paclitaxel has been approved
for clinical use and ABT-578 also appears promising
(Meredith 2003). Angiopeptin and c-myc antisense also has
been tested in clinical trials. Migration inhibitors (eg,
batimastat) are aimed at preventing smooth muscle cell from
migrating into the inside of the stent. If smooth muscle cells
migrate to the luminal side of the stent, they can produce
extracellular matrix and narrow the vascular lumen (Tanabe,
Regar, et al 2004). Therefore, inhibition of smooth muscle
cell migration may have therapeutic applications for
preventing ISR. Examples of these compounds are
batimastat and halofuginone (Tanabe, Regar, et al 2004).
Batimastat inhibits matrix metalloproteinase enzymes and
prevents the matrix degradation that is necessary for cells
to free themselves to move and invade the stent area
(Chevalier 2002). However, a clinical study using batimastat-
coated stent failed to show a reduction in restenosis rate
when compared with BMS (Chevalier 2002). Enhanced
healing factors promote healing of the stent implantation
site by reducing platelet aggregation and increasing the rate
of re-endothelialization (Tanabe, Regar, et al 2004).
Estradiols and nitric oxide donor compounds may also
replicate this effect (Abizaid 2003; Constantini 2003). A
unique approach of promoting the healing process has been
the use of CD34 antibodies-coated stents in order to capture
the circulating endothelial progenitor cells (Tanabe, Regar,
et al 2004). In this experimental model, the surface of the
Table 1 Agents used in drug-eluting stent
Antineoplastics and Enhanced healing and
antiinflammatory Migration inhibitors re-endothelialization
immunomodulators Antiproliferative and ECM modulators  factors
Sirolimus  QP-2, Taxol (paclitaxel) Batimastat  BCP671
Tacrolimus Actinomycin Prolyl hydroxylase inhibitors  VEGF
Everolimus  Methotraxate Halofunginone  Estradiols
Leflunomide Angiopeptin C-proteinase inhibitors  NO donor compounds
M-Prednisolone  Vincristine Probucol  EPC antibodies
Dexamethasone Mitomycine Biorest
Interferon r-1b Statins
Mycophenolic acid C-myc antisense
Mizoribine Abbott ABT-578
Cyclosporine RestenASE
Tranilast  2-choloro-deoxyadenosine
PCNA ribozyme
Abbreviations: ECM, extracellular matrix; EPC, endothelial progenitor cells; NO, nitric oxide; PCNA, proliferating cell nuclear antigen; VEGF, vascular endothelial
growth factor; QP-2, 7-hexanoyltaxol.
A B C D
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Figure 4 Different types of stent-based drug delivery system: (A) Drug
released by diffusion from polymer, (B) Drug released by diffusion through rate-
limiting coating, (C) Drug released by swelling of coating, (D) Drug release
directly from coating, (E) Drug loaded in pore or reservoir in stent, (F) Drug
release by erosion of polymer coating, (G) Drug loaded in nanoporous reservoir
in coating, (H) Drug loaded between coating layers, (I) Drug released by hydrolysis
or enzymatic action from polymer, (J) Bioerodable polymer coating stent.Vascular Health and Risk Management 2005:1(4) 268
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stent was completely re-endothelialized within 48 hours
following stent deployment (Tanabe, Regar, et al 2004). A
first human clinical trial using CD34 antibodies-coated stent
has been completed with a result of safety and feasibility in
the treatment of de novo coronary artery disease (Aoki et al
2005). Therefore, an ideal agent should exert sufficient anti-
restenotic effects, but also allow re-endothelialization and
adequate vessel healing at the site of implantation. It should
also have negligible or no systemic effects (Marx et al 1995;
Sousa et al 2003a, 2003b). Only 2 antiproliferative agents,
sirolimus and paclitaxel, have been proved to be effective
in clinical trials to date (Sousa et al 2003a, 2003b).
Sirolimus (rapamycin), a fermentation product of
Streptomyces hygroscopicus, was discovered in 1977 as an
antifungal macrolide antibiotic with potent immuno-
suppressive properties (Poon et al 1996; Marx et al 2001;
Sousa, Sousa, et al 2003). Since sirolimus is a lipophilic
molecule, it readily diffuses across the cell membranes of
vascular smooth muscle cells and leukocytes. Once in the
cytoplasm, it binds with high affinity to a specific
intracellular protein (FKBP12), and the resultant complex
inhibits a regulatory enzyme, called TOR (target of
rapamycin). Ultimately it blocks cell cycle progression from
G1 to S phase, and therefore limits smooth muscle replication
and proliferation (Poon et al 1996; Marx et al 2001; Sousa,
Sousa, et al 2003).
Paclitaxel is an antineoplastic agent originally isolated
from the bark of the Pacific yew tree, Taxus brevifolia (Schiff
et al 1979; Sollott et al 1995). It was approved by FDA for
treatment of breast and ovarian cancer in 1992. It is also a
lipophilic molecule that readily diffuses across cell
membranes and has a potent stabilizing effect on
microtubules (Schiff et al 1979; Sollott et al 1995). Since
microtubule disassembly is essential for the progression of
the G2 to M phase in the mitotic cell cycle, stabilization of
microtubule inhibits the mitosis of smooth muscle cell as
well as inhibits the cell migration. This reduces the
infiltration of vascular smooth muscle cells and leukocytes
into the zone of injury caused by stent (Schiff et al 1979;
Sollott et al 1995).
Commercially available DES
The sirolimus-eluting Cypher
TM stent (Cordis Corp, a
Johnson and Johnson Company, Miami, FL, USA) was
approved by FDA in April 2003. It is coated with a layer of
nonerodable polymer, of 5 µm–10 µm thickness, which is
incorporated with sirolimus (140 µg sirolimus/cm2 of stent
surface area). An additional topcoat is placed on it as a
Table 2 Clinical trials using agents excluding sirolimus and paclitaxel
Tacrolimus PRESENT I–III Preliminary safety evaluation of nanoporous tacrolimus-eluting stents
EVIDENT The endovascular investigation determining the safety of new tacrolimus-eluting stent grafts
Everolimus FUTURE I–IV First used to underscore reduction in restenosis with everolimus
SPIRITS-FIRST
M-Prednisolone IMPRESS Immunosuppressive therapy for the prevention of restenosis after coronary artery stent
implantation
Dexamethasone STRIDE The study of antirestenosis with BiodivYsio dexamethasone-eluting stent
EMPEROR Evaluation of 9α-F-16 methylprednisolone (dexamethasone)-eluting stent on the reduction of
restenosis
DESIRE Dexamethasone-eluting stent Italian registry
SAFE Sorin and aspirin following elective stenting
Mycophenolic acid IMPACT Inhibition with MPA of coronary restenosis trial
Batimastat BATMAN  BiodivYsio batimastat SV stent versus balloon angioplasty for the reduction of restenosis in small
coronary arteries
BRILLIANT Batimastat (BB-94) antirestenosis trial utilizing the BiodivYsio local drug delivery PC stent
Actinomycin ACTION Recruitment in the actinomycin-eluting stent improves outcomes by reducing neointimal
hyperplasia
Angiopeptin SWAN Stent with angiopeptin 
C-myc antisense RESTEN-NG
Medtronic ABT-578 ENDEAVOR I–III Randomized controlled trial to evaluate the safety and efficacy of the Medtronic AVE ABT-578-
eluting driver
TM coronary stent in de novo native coronary artery lesions
Abbott ABT-578 Zomaxx 1 Zomaxx coronary drug-eluting stent for de novo lesion in coronary arteries.
Estradiols EASTER Estrogen and stent to eliminate restenosis
NO donor compounds NOBLESSE Nitric oxide through biodegradable layer elective study for safety and efficacy
EPC antibodies HEALING I–II Healthy endothelial accelerated lining inhibits neointimal growth
Abbreviations: MPA, mycophenolic acid; PC, phosphorylcholine; SV, small-vessel.Vascular Health and Risk Management 2005:1(4) 269
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diffusion barrier, which provides the vehicle for controlled
release of the drug. It is designed as such that approximately
80% of the total dose of the agent is released in 4 weeks
and the remainder over the course of the next 2 weeks (Wong
and Chan 2004). The second commercially available DES
is the Taxus
TM stent (Boston Scientific, Natrick, MA, USA),
which has a proprietary platform, the Express
TM stent, and
is coated with a proprietary polymer (TransluteTM) loaded
with 1 µg of paclitaxel/mm
2 of stent surface area. Although
there are three drug-release formulations (slow, moderate,
and fast), only moderate- and slow-release formulations have
been tested in clinical trials (Sahatjian 2003; Waugh and
Wagstaff 2004). The moderate-release (MR) form of Taxus
stent allows for an initial bolus release over the first 48 hours
after stenting followed by a low-level release over at least
the next 10 days. In the initial 10 days of drug release, the
slow-release (SR) formulation of Taxus stent has a drug
release concentration of 8–10 times lower than that of the
MR formulation. Only SR formulation is used in FDA
approved Taxus stents. (Sahatjian 2003; Waugh and Wagstaff
2004).
Clinical trials of DES
The initial feasibility study of sirolimus-eluting stent (SES),
the First In Man (FIM) study, consisted of 45 patients with
angina pectoris (Sousa et al 2001; Sousa, Costa, et al 2003).
There were no major adverse cardiac events (MACE); ie,
death, myocardial infarction, coronary bypass grafting, or
target lesion revascularization (TLR) at 1- and 2-year clinical
follow-up; only minimal neointimal hyperplasia within the
stent on angiographic and intravascular ultrasound (IVUS)
follow-up at 1 year; and 10% TVR rate for the entire cohort
at 2 years (Sousa et al 2001; Sousa, Costa, et al 2003). The
first randomized clinical trial of SES, the RAVEL
(Randomized study with the sirolimus-eluting Bx Velocity
balloon-expandable stent) trial, compared the Cypher stent
with BMS-Bx Velocity stent in single, noncomplex lesion
of native coronary arteries. The RAVEL study result
remarkably showed 0% binary restenosis in the SES arm vs
26.6% in the BMS arm at 6-month follow-up, and 5.8%
MACE rate in the SES arm vs 28.8% (p < 0.001) in the BMS
arm at 1-year follow-up (Morice et al 2002; Serruys et al
2002). The effect of SES in more complex lesions was
further confirmed in the larger American trial; SIRIUS
(Sirolimus-coated Bx Velocity balloon-expandable stent in
the treatment of patients with de novo coronary artery
lesions). SIRIUS included a greater proportion of patients
with high-risk features of restenosis such as diabetes, smaller
vessels, and longer lesion requiring overlapping stents. This
study showed a restenosis rate of 8.9% in the SES arm vs
36.3% (p < 0.001) in the BMS arm angiographically
 at
9-month follow-up (Moses et al 2003). Additional similar
SIRIUS trials using SES in Europe and Canada (E- and C-
SIRIUS) showed consistent, impressive results. These two
studies included a total of 452 patients and had binary
restenosis rates 5.9%, 2.3%, respectively, in the SES arm
vs 42.3%, 52.3% (p = 0.0001, p < 0.001) in the BMS arm.
The MACE rate was 8.0%, 2.0%, respectively, in the SES
arm vs 22.6%, 19.0%, respectively (p = 0.0002, p = 0.0002),
in the BMS arm. The TLR rate was 4.0%, 4.0% in the SES
arm vs 20.9%, 18%, respectively (p < 0.0001, p = 0.05), in
the control arm
 at 9-month follow-up (Schofer et al 2003;
Schampaert et al 2004). Results of these clinical trials are
summarized in Table 3.
Table 3 Summary of randomized controlled trials of sirolimus-eluting stent vs bare metal stent
RAVEL SIRIUS E-SIRIUS C-SIRIUS
Sirolimus Control Sirolimus Control Sirolimus Control Sirolimus Control
(n = 120) (n = 118) (n = 533) (n = 525) (n = 175) (n = 177) (n = 50) (n = 50)
Mean lesion length (mm) 9.56 9.61 14.4 14.4 14.9 15.1 14.5 12.6
Mean RVD (mm) 2.6 2.64 2.79 2.81 2.6 2.51 2.65 2.62
Angiographic follow-up 6 mon 9 mon 9 mon 9 mon
Mean late luminal loss
* (mm) –0.01 0.80 0.24 0.81 0.19 0.80 0.12 0.79
Binary restenosis(%) 0 26.6 8.9 36.3 5.9 42.3 2.3 52.3
Subacute stent thrombosis (%) 0 0 0.4 0.8 1.1 0 2.0 2.0
TVR (%) 0 26 3.4 4.8 4.0 20.9 - -
TLR (%) 0 23.7 4.1 16.6 4.0 20.9 4.0 18.0
Overall MACE (%) 5.8 28.8 7.1 18.9 8.0 22.6 4.0 18.3
Abbreviations: RAVEL, Randomized study with sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery
lesion; SIRIUS, Sirolimus-coated BX Velocity stent in the treatment of patients with de novo coronary artery lesions; E- & C- SIRIUS, European- & Canadian-SIRIUS;
MACE, major adverse cardiac events; mon, months; RVD, reference vessel diameter; TLR, target lesion revascularization; TVR, target vessel revascularization.
NOTE: All mean late luminal loss were in-segment except for RAVEL which was in-stent.Vascular Health and Risk Management 2005:1(4) 270
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Unlike SES, paclitaxel and its derivatives have been
studied in different coatings and stent designs. There were
mainly 3 types of paclitaxel coatings: (1) 7-hexanoyltaxol
which used polyacrylate sleeves as a release mechanism
tested in the SCORE (Study to compare restenosis rate
between QueSt and QuaDS-QP2) trial; (2) Paclitaxel-eluting
stent (PES), which used nonpolymer coating as platform
tested in 3 other trials; ELUTES
 (European evaluation of
paclitaxel-eluting stent), ASPECT
 (Asian paclitaxel-eluting
stent clinical trial), and DELIVER
 (Paclitaxel-coated
 RX
ACHIEVE coronary stent system [CSS] versus the RX ML
PENTA
 stainless steel stent in the treatment of focal de novo
coronary
 lesions); and (3) PES which used polymer coating
as a platform tested in TAXUS I–VI trials (Grube et al 2002;
Hong et al 2003; Gershlick et al 2004; Lansky et al 2004).
Except for the polymer-coated-PES, the other two types of
coating have not been very suitable or useful (Grube et al
2002; Hong et al 2003; Gershlick et al 2004; Lansky et al
2004). The initial feasibility study of polymer-based PES,
TAXUS I, was performed in Europe where the feasibility
of using a SR-PES to treat short (< 15 mm) de novo lesions
was demonstrated (Grube et al 2003). TAXUS II was the
first randomized trial using both SR- and MR-PESs with a
binary restenosis rate of 5.5% in SR and 8.6% in MR,
respectively, vs 21.9% in BMS arm (Colombo et al 2003).
TAXUS III was a feasibility trial of SR-PES in ISR with the
result of feasible and safe use in the treatment of ISR in 28
patients with a MACE rate of 29% (Tanabe et al 2003).
TAXUS IV, a major pivotal American trial of PES compared
with BMS, showed significant reduction in the TLR rate
(4.4% vs 15.1%, p < 0.0001), TVR rate (7.1% vs 17.1%,
p < 0.0001), and composite MACE rate (10.8% vs 20.0%,
p < 0.0001) (Stone et al 2004). TAXUS VI was a randomized
trial using MR-PES in complex lesions such as very long
lesions or lesions in small vessels. The results showed in-
stent binary restenosis rate of 12.4% vs 35.7% (p < 0.0001),
TLR rate of 6.8% vs 18.9% (p = 0.0001) and TVR rate of
9.1% vs 19.4% (p = 0.0027) when comparing PES with BMS
arm at 9 months (Dawkins 2004a; Grube 2004). The results
of published randomized controlled trials using PES are
summarized in Table 4.
Other promising DES in clinical trials
Stents coated with rapamycin analogues, ABT-578, and
everolimus were also studied in clinical trials. In the
ENDEAVOR I (Randomized controlled trial to evaluate the
safety and efficacy of the Medtronic AVE ABT-578-eluting
driverTM coronary stent in de novo native coronary artery
lesions) trial, ABT-578 (Abbott Laboratories, Abbott Park,
IL, USA) coated cobalt- alloy stent (Driver stent, Medtronic
Inc, Minneapolis, MN, USA) was used to treat 100 patients
with de novo lesions. The result showed 0.33 mm of
angiographic in-stent late lumen loss at 4 months and
0.58 mm at one-year follow-up. The target-vessel failure rate
was comparable to the results of SIRIUS or TAXUS IV
(Meredith 2003). ENDEAVOR II and III are large pivotal
trials for ABT-578 and the results are pending. FUTURE
(First used to underscore reduction in restenosis with
everolimus) I and II trials were designed to demonstrate the
safety and feasibility of the everolimus-eluting-stent
(Novartis Pharma AG, Basel, Switzerland) in a small
population with focal de novo coronary artery lesions with
a in-stent late lumen loss of 0.12 mm, a low TLR rate (4.3%)
and a very low MACE rate (6.4%) at 6-month follow-up
(Costa et al 2003). A large clinical trial for everolimus-
eluting stent is ongoing.
Table 4 Summary of randomized controlled trials of paclitaxel-eluting stent vs bare metal stent
TAXUS I TAXUS II TAXUS IV TAXUS VI
Control SR Control SR MR Express Taxus Control MR
(n = 30) (n = 31) (n = 270) (n = 131) (n = 135) (n = 652) (n = 662) (n = 227) (n = 219)
Lesion length (mm) 11. 9 10. 7 10. 6 10. 6 10. 2 13. 4 13. 4 20. 32 20. 94
RVD (mm) 2. 94 2. 99 2. 78 2. 8 2. 7 2. 75 2. 75 2. 77 2. 81
Late luminal loss (mm) 0.71 0.36 0. 78 0. 31 0. 3 0. 61 0. 23 0. 99 0. 39
In-stent binary restenosis (%) 10 0 21. 9 5. 5 8. 6 26. 6 7. 9 32. 9 9. 1
Stent thrombosis (%) 0 0 0 1. 5 0. 7 0. 8 0. 6 0 0
TLR or TVR (%) 10 or 0 or 17.5 10.1 6. 9 12.0 4. 7 18. 9 or 6. 8 or
10 3.3 19. 4 9. 1
Overall MACE (%) 10 3. 3 21.7 10.9 9. 9 15.0 8. 5 22.5 16.4
Abbreviations: MACE, major adverse cardiovascular events; MR, moderate-release; RVD, reference vessel diameter; SR, slow-release; TLR, target lesion
revascularization; TVR, target vessel revascularization.Vascular Health and Risk Management 2005:1(4) 271
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Real world experience of DES
The “real world” registries are important because patients
in clinical trials of DES are highly selected groups of patients
and these clinical trials do not include patients with high-
risk lesions for restenosis such as small-vessel, very long
lesions, ostial lesions, left main lesions, bifurcation lesions,
totally occluded and saphenous vein lesions, and lesions in
acute myocardial infarction. However, these registries gather
the clinical outcomes of DES use in unselected population
to further validate its clinical efficacy. SES currently has
2 major registries, RESEARCH and E-Cypher. PES has 3
major registries, WISDOM, MILESTONE II, and ARRIVE.
The RESEARCH (Rapamycin-eluting stent evaluated at
Rotterdam Cardiology Hospital) registry is a single-center
registry of an unrestricted use of SES in all patients with de
novo lesions to evaluate the safety and efficacy in the daily
practice at 1-year period compared with a control group
who received BMS in the previous year. This registry had
excellent results with lower TLR rate (5.1% vs 10.9%) and
MACE rate (9.7% vs 14.8%) (Lemos, Serruys, et al 2004).
E-Cypher is an international internet-based registry of
SES that enrolled all patients receiving one and more SES
with current recruitment of more than 12 000 patients in
275 international sites and more than 80% eligible patients
at 6-month follow-up. This registry showed absolutely
stunning outcomes of 2.95% MACE rate, 1% TLR rate, and
0.3% SAT rate at 6 months (Urban 2003). WISDOM (Web-
based Taxus intercontinental observational data transitional
registry program) was a multicenter registry of 778 patients
who received PES without strict clinical and angiographic
inclusion criteria. The interim result of this registry showed
a TLR rate of 1.8% and a MACE rate of 4.5% (Abizaid
2004). MILESTONE II was a European and intercontinental
post-market registry of 3708 patients who received PES
compared with the result of MILESTONE I which used
BMS. MILESTONE II included the high-risk lesions and
diabetic patients, especially insulin dependent diabetes, and
it also had successful results of 7.1% MACE rate, 4.2% of
TVR rate and 0.9% of stent thrombosis rate (acute and late
angiographic restenosis) at 6 months with the diabetic
population having 8.9% MACE rate and 5% TVR rate
(Boston Scientific Corporation 2004). ARRIVE is a peri-
approval Taxus stent registry of 2600 consecutive patients
at 50 centers in USA and showed the result of 2.7% MACE
rate and 1.3% of stent thrombosis rate at 30 days (Cox 2004).
The clinical outcomes of these registries showed that the
use of DES in the real world practice, ie, in a larger and
unselected patient population, achieved similarly successful
outcome as those of previous randomized trials.
Current issues of DES
Expanded indications
Although DES was proved to be a safe and effective method
in the treatment of coronary artery stenosis by both
randomized clinical trials and real world practice, its
expanded indications in complex and high-risk lesions for
restenosis such as totally occluded lesions, left main lesions,
bifurcation lesions, ostial lesions, small and long lesions,
saphenous vein graft lesion, ISR, and diabetes mellitus are
still under evaluation with ongoing trials. The results of
clinical trials for some expanded indications are now
available.
Of the high-risk subsets, diabetes mellitus is the most
common and important one. Subanalysis of diabetic patients
in the many clinical trials such as SIRIUS, TAXUS IV, or
E-Cypher registry showed a great efficacy of DES in these
patients even though these trials were not designed to
investigate the efficacy in diabetes mellitus. SIRIUS study
showed excellent results with a MACE rate of 9.2% vs 25%
(p < 0.001) and a TLR rate of 6.9% vs 22.3% (p < 0.001) in
the SES arm compared with the BMS arm at 9-month follow-
up (Moussa et al 2004). In the diabetic group of the
E-Cypher registry, the results were 4.2% MACE, 1.4% TLR,
and 0.5% SAT with similar result in insulin dependent
diabetic subset; 5.9% MACE, 1.5% TLR, and 0.4% SAT
(p < 0.01) (Gershlick 2003). In the TAXUS IV trial, similar
results were shown in diabetic patients with a binary
angiographic restenosis rate of 6.4% in PES arm vs 34.5%
in BMS arm (p < 0.0001) at 9-month follow-up, the TLR
rate of 7.4% vs 20.9% (p = 0.0008) and TVR rate of 11.3%
vs 24% (p < 0.004), respectively, at 12-month follow-up.
More specifically, in insulin dependent diabetic subset, a
very similar rate of angiographic restenosis 7.7% vs 42.9%
(p = 0.0065), and TLR rate of 6.2% vs 19.4% (p = 0.07),
when compared with BMS was found to exist (Hermiller
2005). A large comparison study using DES in treating
multi-vessel disease in diabetic patients with coronary
bypass surgery is currently ongoing.
In the subset of the lesions in small vessels, the data
from the RESEARCH registry showed that the larger vessels
group (reference vessel diameter of 2.52 mm ± 0.57 mm) has
a late loss of 0.03 mm ± 0.38 mm and binary restenosis rate
of 3.9% whereas the small vessels group (reference vessel
diameter of 1.88 mm ± 0.34 mm) has a late loss ofVascular Health and Risk Management 2005:1(4) 272
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0.07 mm ± 0.48 mm and a restenosis rate of 10.7%. (Lemos,
Arampatzis, et al 2004). In the SIRIUS trial, the small vessel
(reverence vessel diameter [RVD] ≤ 2.3 mm) subset study
showed an in-lesion restenosis rate of 18.6% in the SES
group vs 42.9% in the control group (p < 0.001) (Guagliumi
2004). Moreover, with an improved deployment technique
to cover the full length of lesions, a different trial, ie, Small
vessels treated with the Cypher stent (SVELTE) was
performed. The SVELTE trial was a prospective study using
Cypher stent in small-vessel lesions (RVD of 2.25 mm–
2.75 mm) while comparing the historical control from the
SIRIUS trial. The findings indicated a better in-stent binary
restenosis rate of 3.2% in SVELTE group vs 3.9% in
SIRIUS-SES group and 38.0% in SIRIUS-control group
with much improved in-lesion restenosis rate of 6.3% vs
11.6% and 39.0%, respectively (Sousa 2004).
For very long lesions, the study from the RESEARCH
registry examining patients with long lesions with a SES
stent length of 39 mm ± 29 mm (mean ± standard deviation)
showed an in-stent late loss 0.13 mm ± 0.47 mm at 6-month
follow-up and a TVR rate of 6.2% and a MACE rate of
8.3% at 320-day follow-up (Degertekin et al 2004). The
TAXUS VI study for very long lesions (18 mm–40 mm in
lesion length) showed a very impressive low TLR rate of
6.8% in the PES arm vs 18.9% in the BMS arm at 9 month
follow-up (Dawkins 2004b).
In a totally occluded lesion substudy, the data from
RESEARCH registry showed a reduction in the MACE rate
(cumulative MACE-free survival rate of 96.4% in SES arm
vs 82.1% in BMS arm) and a binary restenosis rate of 9.1%
in the SES arm vs other BMS trials for total occluded lesions:
55% in TOSCA (Total occlusion study of Canada); 42% in
STOP (Stents in total occlusion for restenosis prevention);
32% in GISSOC (Gruppo italiano di studio sullo stent nelle
occlusioni coronariche) and 32% in SICCO (Stenting in
Chronic Coronary Occlusion) (Hoye et al 2004). In addition,
SICTO (Sirolimus-eluting stent in chronic total occlusion)
was a multicenter, prospective and nonrandomized
feasibility study of SES in treatment of patients with chronic
total occlusion and showed a persistently pristine result of
late loss (–0.1 mm ± 0.3 mm) and a TVR rate of 8% at 6-
month follow-up (Lotan 2004).
For the treatment of in-stent restenosis, TAXUS III trial,
a feasibility and safety study, showed a result of 21% TLR
rate and a binary restenosis rate of 16% in the PES arm
(Tanabe et al 2003). In RESEARCH registry, the SES group
had the results of a MACE rate of 18.6% and a TVR rate of
4.7% similar to the results of the brachytherapy group,
20.9%, 4.7%, respectively, at 9-month follow-up (Saia et al
2004). But much more strikingly, TROPICAL (Sirolimus-
eluting stent in the treatment of patients with in-stent
restenotic native coronary artery lesion) was a multicenter,
nonrandomized study that showed a much better result of
stent thrombosis rate (0.6% vs 3.9%), binary restenosis rate
(9.7% vs 40.3%), and MACE rate (3.7% vs 18.8%) in the
SES arm when compared with the historic control from the
brachytherapy trials (GAMMA I and II) (Neumann et al
2004). The ISAR-DESIRE (Intracoronary stenting and
angiographic results: drug-eluting stent for in-stent
restenosis) trial was a 3-arm study comparing the efficacy
of SES, PES, and BA in patients with ISR. Both SES and
PES were associated with a lower TVR rate and smaller
late lumen loss than use of BA at 9 months (Kastrati 2004).
In patients with bifurcation lesions, RESEARCH registry
showed encouraging TLR rate (8.6%) and binary restenosis
rate (22.7%) in SES group (Tanabe et al 2004). Colombo et
al (2004) described a safety and efficacy of SES in the
treatment of bifurcation lesion with the result of TLR rate
of 17.6% and binary restenosis rate of 25.7% but it was
concluded that restenosis at the side branch remained a
problem (Colombo et al 2004). The use of DES in left main
lesion and the vein graft lesion is still under clinical
investigation.
In terms of the superiority of DES, two large randomized
clinical trials in head-to-head comparison of the efficacy of
SES to PES in patients with de novo lesions, ie, REALITY
(A prospective, randomized, multi-center comparison of the
cypher sirolimus-eluting and the Taxus paclitaxel-eluting
stent systems) and SIRTAX (Randomized comparison of a
sirolimus- vs a paclitaxel-eluting (Taxus) stent for coronary
revascularization) were recently completed. The result of
REALTY trial showed no difference between SES and PES
in binary angiographic in-lesion restenosis at 8 months
(9.6% Cypher vs 11.1% TAXUS), but all angiographic
parameters favored more robust inhibition of neointimal
hyerplasia by Cypher (in-stent late loss: 0.09 mm vs
0.31 mm; diameter stenosis%: 23.1% vs 26.7%; in-stent
minimal luminal diameter: 2.0 mm vs 1.85 mm) (Morice
2005). In the SIRTAX trial, SES showed a lower in-stent
and in-lesion late luminal loss than PES (0.13 mm vs
0.25 mm, 0.19 mm vs 0.32 mm respectively) as well as a lower
in-stent and in-lesion binary restenosis than PES (3.2% vs
7.6%, 6.7% vs 11.9%, respectively) (Windecker 2005).Vascular Health and Risk Management 2005:1(4) 273
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SAT and late stent thrombosis
Subacute stent thrombosis is approximately 1% in patients
on dual antiplatelet therapy. However, an IVUS study has
revealed that inadequate stent expansion was related to SAT.
An adequate stent expansion and IVUS guided stent
implantation had been shown to reduce the SAT rate
(Moussa et al 1997). However, there was a case report of an
occurrence of late stent thrombosis in one patient who
discontinued clopidogrel at 18 month after SES implantation
(Virmani et al 2004). Subsequetly, a 2nd case report revealed
four patients developed similar late stent thrombosis
following the discontinuation of clopidogrel after 1 year of
PES implantation. (McFadden et al 2004). This has raised
the question of whether there is a need to increase the
duration of antiplatelet therapy for patients receiving DES
beyond the current recommended guidelines of practice.
Issue of stent-based delivery:
incomplete stent apposition and uneven
stent strut distribution
Incomplete stent apposition (ISA), defined as one or more
stent struts not in contact with vascular wall on IVUS at
any point in time after stent implantation, was found in 21%
of the SES arm in RAVEL vs 4% in the BMS arm at 6-
month follow-up (Serruys et al 2002). It is possible that this
is due to either an initial incomplete deployment of stent
during implantation or positive remodeling of vessel wall
but other mechanisms like plaque regression, cell necrosis,
apoptosis, and allergic reaction to sirolimus have been
postulated (Lemos et al 2003; Takebayashi et al 2004).
Uneven stent strut distribution and incomplete wall
apposition has been considered to be the causes of ISR after
the DES implantation in two clinical studies (Lemos et al
2003; Takebayashi et al 2004).
Economic burden
One of the thorniest issues regarding DES is their cost and
reimbursement. In the USA, a BMS costs approximately
$900–$1200 each while a DES costs approximately $3065–
$3195. However, in the cost-effective analysis of SIRIUS
trial, the difference of cost between the 2 groups were only
about US $300 at 1 year, despite an initial $3000 difference
after hospitalization (Cohen et al 2003). The advent of more
varieties of DES in near future will minimize the cost issue
and make DES available to all patients.
Conclusion
The recent introduction of DES in PCI is a major innovative
advancement in interventional cardiology. DES dramatically
reduces the ISR rate in all subgroups of patients in both
randomized clinical trials and real-world practice.
Continuing improvement in drug-delivery stent technologies
and gradual reduction in cost would make DES an effective
mainstay of therapy for coronary artery disease.
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